Intraarterial infusion of dibutyryl cyclic adenosine monophosphate plus mitomycin C for unresectable hepatocellular carcinoma: Long-term survival and response to tumor growth inhibition

Hepatocellular carcinoma (HCC) is the most common liver neoplasm in dogs and can be treated by the Viscum album therapy in a curative or palliative way. The objective is to report a hepatocellular carcinoma case in a dog treated by homeopathic therapy, extending to Palliative Care, with a 24-month survival. A 12-year-old Schnauzer male with a history of a liver nodule was treated by intravenous and subcutaneous applications of V. album in different dynamization and combinations, chromotherapy, and oral homeopathic medicines. The tumor growth was controlled, and the health condition of the patient was stable while the medication was given as prescribed. However, as application frequency was reduced, tumor growth increased, and health deterioration was verified. Nevertheless and contrary to expectations, the patient had a 24-month survival. Therefore, these findings point to the potential of V. album on enhancing the quality of life, controlling tumor growth, and prolonging survival on patients with HCC. Patients under continuous treatment would benefit better of these properties.

Download Full-text

Activation of Ras/MAPK and mTOR pathways in hepatocellular carcinoma: Tumor growth inhibition with Ras/mTOR pathway abrogation by a novel combination of Sorafenib and rapamycin

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2007.06.234 ◽

2007 ◽

Vol 205 (3) ◽

pp. S93-S94

Author(s):

Philippa H. Newell ◽

Augusto Villanueva ◽

Judit Peix ◽

Isabel Fiel ◽

Swan Thung ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Tumor Growth ◽

Growth Inhibition ◽

Mtor Pathway ◽

Tumor Growth Inhibition ◽

Carcinoma Tumor

Download Full-text

Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models

Angiogenesis ◽

10.1007/s10456-012-9328-3 ◽

2012 ◽

Vol 16 (2) ◽

pp. 429-441 ◽

Cited By ~ 22

Author(s):

Alexandra Eichten ◽

Alexander P. Adler ◽

Blerta Cooper ◽

Jennifer Griffith ◽

Yi Wei ◽

...

Keyword(s):

Tumor Growth ◽

Growth Inhibition ◽

Rapid Decrease ◽

Tumor Growth Inhibition ◽

Tumor Perfusion ◽

Tumor Models

Download Full-text

Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-012-1270-7 ◽

2012 ◽

Vol 138 (11) ◽

pp. 1879-1890 ◽

Cited By ~ 12

Author(s):

Fan Zhou ◽

Juan Hu ◽

Jiang-Hua Shao ◽

Shu-Bing Zou ◽

Shun-Li Shen ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Tumor Growth ◽

Growth Inhibition ◽

Metronomic Chemotherapy ◽

Tumor Growth Inhibition ◽

Antiangiogenic Treatment

Download Full-text

Tumor growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T-cell costimulation via CD28

Immunology Letters ◽

10.1016/s0165-2478(97)88217-x ◽

1997 ◽

Vol 56 (1-3) ◽

pp. 340

Author(s):

L Hovest

Keyword(s):

T Cell ◽

Tumor Growth ◽

Growth Inhibition ◽

Bispecific Antibody ◽

Antibody Fragments ◽

Tumor Growth Inhibition ◽

Syngeneic Mouse ◽

Mouse Melanoma Model ◽

Melanoma Model

Download Full-text

Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy

Scientific Reports ◽

10.1038/s41598-021-95835-5 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Bin-yong Liang ◽

Jin Gu ◽

Min Xiong ◽

Er-lei Zhang ◽

Zun-yi Zhang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Tumor Size ◽

Staging System ◽

Prognostic Impact ◽

Term Survival ◽

Long Term Survival ◽

Before And After ◽

Cirrhotic Patients ◽

Curative Hepatectomy

AbstractHepatocellular carcinoma (HCC) is usually associated with varying degrees of cirrhosis. Among cirrhotic patients with solitary HCC in the absence of macro-vascular invasion, whether tumor size drives prognosis or not after hepatectomy remains unknown. This study aimed to investigate the prognostic impact of tumor size on long-term outcomes after hepatectomy for solitary HCC patients with cirrhosis and without macrovascular invasion. A total of 813 cirrhotic patients who underwent curative hepatectomy for solitary HCC and without macrovascular invasion between 2001 and 2014 were retrospectively studied. We set 5 cm as the tumor cut-off value. Propensity score matching (PSM) was performed to minimize the influence of potential confounders including cirrhotic severity that was histologically assessed according to the Laennec staging system. Recurrence-free survival (RFS) and overall survival (OS) were compared between the two groups before and after PSM. Overall, 464 patients had tumor size ≤ 5 cm, and 349 had tumor size > 5 cm. The 5-year RFS and OS rates were 38.3% and 61.5% in the ≤ 5 cm group, compared with 25.1% and 59.9% in the > 5 cm group. Long-term survival outcomes were significantly worse as tumor size increased. Multivariate analysis indicated that tumor size > 5 cm was an independent risk factor for tumor recurrence and long-term survival. These results were further confirmed in the PSM cohort of 235 pairs of patients. In cirrhotic patients with solitary HCC and without macrovascular invasion, tumor size may significantly affect the prognosis after curative hepatectomy.

Download Full-text